[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336247-105":59,"doc-detail-336247-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","who-2022-updates-on-follicular-cell-and-c-cell-derived-thyroid-neoplasm-a-review","WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm - A review","","The latest edition of the WHO Classification of thyroid tumors was released in 2022 and introduces novel concepts important for patient management. It redefines terms and grading approaches for thyroid follicular nodular disease and explains benign, low-risk, and malignant follicular cell–derived neoplasms. The review highlights subtyping papillary thyroid cancer using histomorphologic indicators rather than size alone, updates terminology for differentiated high-grade carcinoma, and describes newly characterized morphologic patterns in anaplastic subtypes. It summarizes key revisions to the WHO thyroid cancer classification.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/who-2022-updates-on-follicular-cell-and-c-cell-derived-thyroid-neoplasm-a-review/336247/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/who-2022-updates-on-follicular-cell-and-c-cell-derived-thyroid-neoplasm-a-review/336247.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are the key WHO 2022 updates regarding thyroid tumors?","Question",{"text":113,"@type":114},"The 2022 WHO classification adds novel concepts that affect how thyroid tumors are managed, including updated terminology, grading, and prognostication based on pathologic features and molecular profiles.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why does the classification emphasize subtyping papillary thyroid cancer beyond tumor size?",{"text":118,"@type":114},"It avoids treating all lesions under 1 cm as uniformly low-risk and instead uses histomorphologic indicators to guide accurate risk stratification and subtype assignment.",{"name":120,"@type":111,"acceptedAnswer":121},"What does “thyroid follicular nodular disease” aim to address?",{"text":122,"@type":114},"It provides an alternative collective term for a wide range of benign and non-neoplastic lesions, helping avoid problematic labeling such as hyperplasia, adenomatous, or adenomatous hyperplasia.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336247,1790040405,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","JOURNAL of MEDICINE and LIFE  \nJML | REVIEW  \nWHO 2022 updates on follicular cell and c-cell derived  \nthyroid neoplasm  \nParth Goswami1, Tarang Patel1, Rushang Dave1, Gyanendra Singh1*, Anurag Singh2, Tushar Kalonia3  \n1. Department of Pathology, All India Institute of Medical Sciences, Rajkot, Gurjat, India  \n2. King George's Medical University, Lucknow, India  \n3. Department of Pathology, Sharda Hospital, Greater Noida, India  \n* Corresponding author  \nGyanendra Singh  \nDepartment of Pathology,  \nAll India Institute of Medical Sciences, Rajkot, Gurjat, India [E-mail: gyanendra002@gmail.com](E-mail: gyanendra002@gmail.com)  \nDOI  \n10.25122/jml-2023-0270  \nDates  \nReceived: 9 August 2023  \nAccepted: 19 September 2023  \nABSTRACT  \nThe latest edition of the WHO Classification of thyroid tumors was released in 2022 and incorporates novel concepts vital to patient management. Thyroid follicular nodular disease is a term used to collectively represent a wide variety of benign and non-neoplastic lesions, including both clonal and non-clonal proliferations that manifest clinically as multinodular goiter. Thyroid neoplasms develop from follicular cells and can be either benign, low-risk, or malignant. To avoid classifying all lesions under 1 cm in diameter as low-risk illnesses, the new classification method highlights the need for subtyping papillary thyroid cancer based on histomorphologic indicators rather than tumor size. Formerly known as the cribriform-morular variety of papillary thyroid carcinoma, this tumor is now more commonly referred to by its more accurate name, cribriform-morular thyroid carcinoma. Its histogenesis is unknown. Similar to the traditional definition of ‘poorly differentiated thyroid carcinoma’ according to the Turin criteria, the newly defined ‘differentiated high-grade thyroid carcinoma’ encompasses papillary thyroid cancer, follicular thyroid carcinomas, and oncocytic carcinomas with high-grade characteristics linked to worse prognosis. The squamous cell subtype of anaplastic thyroid cancer has also recently been characterized as a distinct morphologic pattern. In this article, we will discuss the latest revision to the World Health Organization's classification system for thyroid cancer.  \nKEYWORDS: Thyroid neoplasm, Follicular cell neoplasm, C-cell neoplasm  \nINTRODUCTION  \nThe fifth edition of the World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors is a timely publication that easily lends itself to years of experience in the field of diagnostic and molecular thyroid pathology. It contains appropriate changes to nomenclature, grading, and prognostication of thyroid proliferations based on pathologic features and molecular profile. Therefore, endocrinologists and practicing physicians who manage thyroid nodules should acquaint themselves with this new classification scheme [1] .  \nThe thyroid gland is the source of the most common endocrine tumors. The clinical entity known as multinodular goiter has been used for pathology diagnosis. However, this is inappropriate and pathologists use the terminology such as hyperplasia, adenomatous, and adenomatoid for such lesion. Clonal events, such as gene mutations, may be the deciding element in explaining why a few multinodular goiters develop into malignancies.  \nAn alternative terminology proposed to address this is ‘thyroid follicular nodular disease’, a term that avoids defining a lesion  \nas hyperplastic, neoplastic, or the contradictory ‘adenomatous hyperplasia’ [2]. According to the most recent classification, follicular adenoma with papillary architecture is included as a new entity, as is shown in table 1 [1] .  \nMolecular analyses of individual nodules in such cases have revealed that a good proportion of goitrous nodules is monoclonaland represent neoplastic proliferations, making it impossible to distinguish between non-neoplastic and benign neoplastic follicular neoplasms, i.e., adenomas based on morphology alone ","cbCaim2cr4iHkVvA","https://ap.wps.com/l/cbCaim2cr4iHkVvA","pdf",758808,"English","# ABSTRACT\n# INTRODUCTION\n## Thyroid follicular nodular disease and terminology\n## Molecular analyses and clonal events\n## Low-risk neoplasms and nomenclature\n## Updates in oncocytic carcinoma and related entities\n## Supplementary Table 1: WHO classification of thyroid neoplasms","[{\"question\":\"What are the key WHO 2022 updates regarding thyroid tumors?\",\"answer\":\"The 2022 WHO classification adds novel concepts that affect how thyroid tumors are managed, including updated terminology, grading, and prognostication based on pathologic features and molecular profiles.\"},{\"question\":\"Why does the classification emphasize subtyping papillary thyroid cancer beyond tumor size?\",\"answer\":\"It avoids treating all lesions under 1 cm as uniformly low-risk and instead uses histomorphologic indicators to guide accurate risk stratification and subtype assignment.\"},{\"question\":\"What does “thyroid follicular nodular disease” aim to address?\",\"answer\":\"It provides an alternative collective term for a wide range of benign and non-neoplastic lesions, helping avoid problematic labeling such as hyperplasia, adenomatous, or adenomatous hyperplasia.\"}]","WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm - A review | PDF",1790014239,23]